Financial Performance - Total revenue for the first half of 2016 was CNY 23,225,168.49, a decrease of 62.15% compared to CNY 61,363,567.18 in the same period last year[16]. - Net profit attributable to shareholders was a loss of CNY 1,678,476.13, representing a decline of 113.56% from a profit of CNY 12,377,741.74 in the previous year[16]. - Operating cash flow for the period was a negative CNY 19,028,895.13, a significant drop of 2,650.75% compared to CNY 746,011.06 in the same period last year[16]. - Basic earnings per share were CNY -0.0126, down 105.66% from CNY 0.2228 in the previous year[16]. - Total assets at the end of the reporting period were CNY 510,316,924.16, a decrease of 1.89% from CNY 520,151,941.71 at the end of the previous year[16]. - Shareholders' equity attributable to ordinary shareholders was CNY 424,338,153.88, down 1.93% from CNY 432,683,630.01 at the end of the previous year[16]. - The weighted average return on net assets was -0.39%, a decrease of 4.70% from 4.31% in the previous year[16]. - The company reported a significant increase in investment activity, with cash flow from investment activities reaching ¥43,832,304.87, a 2,315.32% increase compared to the previous year[35]. - The company experienced a 35.75% decrease in R&D investment, totaling ¥2,475,935.33 for the reporting period[35]. - The company reported a net loss of CNY 307,027.76 for Guangzhou Boji Clinical Research Center Co., Ltd.[44]. Operational Developments - The company is enhancing clinical trial quality standards and personnel training to improve service levels in response to regulatory changes[22]. - The company has established a wholly-owned subsidiary, Guangzhou Jiutai Medical Technology Co., Ltd., to focus on clinical trials for medical devices, with over 20 projects currently under research[30]. - The company is advancing the construction of a "consistency evaluation center" for solid oral preparations, with over 60 personnel involved in the evaluation work[30]. - The company organized two academic seminars on consistency evaluation to enhance technical capabilities and align with national policies[30]. - The company is facing risks from slow clinical trial progress due to regulatory scrutiny, impacting revenue and net profit[28]. - The company plans to participate more in international multi-center clinical research to enhance competitiveness against multinational CROs[24]. - The company is addressing potential disputes arising from clinical trial data self-inspection and the impact on its brand image and operations[22]. Investment and Funding - The company signed a framework agreement to establish a new drug industry investment fund, focusing on pre-market new drug cultivation and R&D projects[33]. - The company completed the construction of a 20,266 square meter biopharmaceutical technology park, which will provide various services including project incubation and clinical trial drug production[33]. - The total amount of raised funds was CNY 188,536,100, with CNY 56,234,000 invested during the reporting period[52]. - CNY 68,709,700 has been cumulatively invested from the raised funds, including CNY 4,985,500 from self-owned funds[53]. - The company reported a total investment commitment of 18,839.5 million CNY for various projects, with 5,623.4 million CNY already utilized[56]. - The company has not encountered any issues regarding the use and disclosure of raised funds during the reporting period[57]. - The company did not engage in any significant non-fundraising investment projects during the reporting period[59]. Shareholder and Equity Information - The company reported a total profit distribution of 6,667,000.00 CNY, with a cash dividend of 0.50 CNY per 10 shares based on a total share capital of 133,340,000 shares as of December 31, 2015[71]. - The cash dividend distribution was completed by June 7, 2016, following the shareholder meeting on May 26, 2016[72]. - The company has maintained a clear and transparent profit distribution policy, ensuring the protection of minority shareholders' rights[73]. - The company has not reported any overdue principal or interest during the reporting period[68]. - The company has a commitment that if the stock price falls below the offering price for 20 consecutive trading days, the lock-up period will be automatically extended by six months[99]. - The company has established a plan to stabilize stock prices within three years post-IPO, which includes increasing shareholdings if the stock price falls below the latest audited net asset value per share[99]. - The company has confirmed that all major shareholders have strictly adhered to their commitments as of the report date[97]. Financial Health and Liabilities - The company's total liabilities at the end of the period were CNY 225,341,000.00, which needs to be monitored for financial health[154]. - The total equity attributable to shareholders was CNY 399,320,768.61, down from CNY 404,744,925.29, representing a decline of approximately 1.1%[132]. - Current liabilities totaled CNY 71,510,464.81, down from CNY 75,978,931.67, reflecting a decrease of approximately 5.8%[132]. - Non-current liabilities were CNY 5,961,880.49, slightly reduced from CNY 6,207,226.08, indicating a decrease of about 4.0%[132]. - The company’s total liabilities and equity at the end of the period were not specified but are critical for assessing financial health[149]. Compliance and Governance - The financial report was approved by the board of directors on August 25, 2016[164]. - The company has maintained its ability to continue operations for at least 12 months from the reporting date[166]. - The financial statements comply with the requirements of the Accounting Standards for Enterprises, reflecting the company's financial position, operating results, and cash flows accurately[169]. - The company operates on a calendar year basis, from January 1 to December 31[170]. - The company has several subsidiaries, including Guangzhou Boji New Drug Clinical Research Center Co., Ltd. and Beijing Zhongwei Bicheng International Pharmaceutical Technology Co., Ltd.[164]. Accounting Policies - The company recognizes revenue based on specific accounting policies tailored to its operational characteristics[167]. - The company categorizes its financial assets into four classes, including financial assets measured at fair value with changes recognized in profit or loss[181]. - The company employs a perpetual inventory system and conducts regular inventory counts[192]. - Financial assets are derecognized when the risks and rewards of ownership are transferred, with the difference between the carrying amount and the consideration received recognized in the current period[184]. - The company assesses the net realizable value of inventory based on estimated selling prices minus estimated selling expenses and related taxes[192].

Financial Performance - The company's operating revenue for 2015 was CNY 126,626,043.64, a decrease of 11.99% compared to CNY 143,873,596.59 in 2014[18]. - The net profit attributable to shareholders for 2015 was CNY 25,663,774.74, down 32.40% from CNY 37,963,575.57 in 2014[18]. - The net cash flow from operating activities was CNY 1,925,986.28, a significant decline of 92.50% compared to CNY 25,687,786.48 in 2014[18]. - Basic earnings per share for 2015 were CNY 0.2008, a decrease of 47.10% from CNY 0.3796 in 2014[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2015 was CNY 3,783,983.93, a decrease from CNY 8,280,387.81 in 2014[21]. - The net cash flow from operating activities was negative CNY 8,120,179.56 in 2015, compared to positive CNY 8,866,190.62 in 2014[21]. - Revenue from clinical research services was CNY 95,920,567.57, accounting for 75.75% of total revenue, with a year-on-year decrease of 9.84%[45]. - Revenue from preclinical research services and independent preclinical R&D decreased by 14.99% and 68.58% year-on-year, respectively[45]. - The gross profit margin for clinical research services was 44.53%, with a decrease of 9.84% in revenue compared to the previous year[57]. Assets and Equity - Total assets at the end of 2015 reached CNY 520,151,941.71, an increase of 67.65% from CNY 310,263,048.17 at the end of 2014[18]. - The net assets attributable to shareholders increased by 98.04% to CNY 432,683,630.01 from CNY 218,483,709.07 in 2014[18]. - The company’s total share capital increased to 133,340,000 shares after a capital reserve conversion in 2015[99]. - The net asset value per share attributable to ordinary shareholders fell from 4.3697 in 2014 to 3.2450 in 2015, a decrease of about 25.7%[139]. - The equity attributable to shareholders increased by 98.04% year-on-year, totaling RMB 432,683,630.01[146]. Research and Development - R&D expenses for 2015 amounted to ¥35,489,953.18, accounting for 55.60% of operating costs, a decrease of 4.23% compared to 2014[60]. - The company has developed five major service platforms for preclinical research, enhancing its capabilities in drug evaluation and development[39]. - The company is committed to enhancing its preclinical research services by improving hardware and software conditions and increasing its capacity for consistency evaluation of generic drugs[85]. - The company has implemented strict standard operating procedures to ensure high-quality research services and rapid problem resolution[37]. Strategic Plans and Market Position - The company plans to strengthen internal management and improve research and development service levels to mitigate risks from policy changes[5]. - The company will enhance project management and collaborate closely with clinical trial institutions to recover project progress[6]. - The company plans to enhance its clinical research services and establish a nationwide monitoring service network, aiming to become a large-scale pharmaceutical research service enterprise with international competitiveness[82]. - The company aims to maintain a stable share price to support its long-term development strategy[106]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[181]. Shareholder and Governance - The company distributed a cash dividend of 0.50 yuan per 10 shares, totaling 6,667,000 yuan for the year 2015, which represents 25.98% of the net profit attributable to shareholders[98]. - The company has committed to not transferring or entrusting the management of its shares for 36 months following its initial public offering[101]. - The company has established a sound governance structure, ensuring compliance with the Corporate Law and the Shenzhen Stock Exchange regulations[191]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[192]. - The company emphasizes investor relations management, utilizing multiple channels for communication and feedback with investors[193]. Risks and Challenges - The company faces risks from policy changes that could impact new drug development and contract fulfillment, potentially affecting revenue[88]. - The company is experiencing project delays due to CFDA's self-inspection and verification work, which may impact its 2016 performance[88]. - The company acknowledges the risk of disputes arising from drug registration applications that may not be approved, affecting its brand image and operations[89]. - The company anticipates a potential decline in R&D investment from domestic pharmaceutical companies, which could impact the number and value of projects it can undertake[93]. Employee and Management Structure - The total number of employees in the company is 420, with 348 in the parent company and 72 in major subsidiaries[186]. - The company has a diverse professional composition, with 241 employees in clinical monitoring, 23 in medical and statistics, 31 in business marketing, 59 in preclinical research, and 66 in management and finance[186]. - The management team emphasized a commitment to sustainability, aiming for a 30% reduction in operational carbon footprint by 2025[183]. - The company has a comprehensive training system that includes various training categories such as corporate culture, technical skills, project management, and management skills[188].

Financial Performance - Total revenue for Q1 2016 was ¥8,487,767.89, a decrease of 64.36% compared to ¥23,814,863.05 in the same period last year[7] - Net profit attributable to shareholders was ¥162,097.50, down 95.88% from ¥3,939,108.93 year-on-year[7] - Basic and diluted earnings per share were both ¥0.0012, representing a decrease of 96.95% from ¥0.0394 in the same period last year[7] - Operating costs decreased by 65.40% to 4.46 million yuan from 12.88 million yuan year-on-year, primarily due to the decline in revenue[18] - The company's cash flow from operating activities decreased by 52.32% compared to the same period last year, mainly due to reduced cash recovery from business operations[19] - The company's total revenue for Q1 2016 was 8.48 million yuan, a decrease of 64.36% compared to 23.81 million yuan in the same period last year[18] - Total operating revenue for Q1 2016 was CNY 8,487,767.89, a decrease of 64.4% compared to CNY 23,814,863.05 in the same period last year[55] - Net profit for Q1 2016 was CNY 162,097.50, a significant decline from CNY 3,939,108.93 in Q1 2015[56] - The company's cash and cash equivalents were CNY 48,978,378.04, down from CNY 55,330,571.91 at the beginning of the year, indicating a decrease of 11.5%[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥512,670,423.61, down 1.44% from ¥520,151,941.71 at the end of the previous year[7] - The total assets decreased from CNY 520,151,941.71 at the beginning of the period to CNY 512,670,423.61 at the end of the period[48] - Total liabilities decreased to CNY 74,567,375.80 from CNY 82,186,157.75 at the start of the year, reflecting a reduction of 9.9%[53] - The total non-current assets increased from CNY 111,215,045.26 at the beginning of the period to CNY 120,137,476.87 at the end of the period[48] Cash Flow - The net cash flow from operating activities was -¥12,368,668.46, a decline of 52.32% compared to -¥8,120,179.56 in the previous year[7] - The company's cash and cash equivalents decreased from CNY 133,013,021.11 at the beginning of the period to CNY 101,797,046.15 at the end of the period[47] - The company's cash flow from operating activities shows a net outflow of CNY -12,368,668.46, worsening from CNY -8,120,179.56 in the previous period[64] - The total cash inflow from operating activities was $12,897,516.12, down from $21,930,026.96 in the previous period[67] - The net cash flow from investing activities was $5,029,597.46, compared to -$733,565.41 in the previous period, showing a significant positive change[68] Shareholder Commitments - The company strictly adhered to the shareholding commitment, with major shareholders not transferring or entrusting their shares within the specified lock-up period[31] - Major shareholders are committed to not transferring more than 25% of their total shares during their tenure, with a six-month restriction post-departure[32] - The company has a policy that any share reduction after the lock-up period must not be below the issuance price[32] - The company has established a commitment to return any proceeds from share reductions to the company[32] - The lock-up period for major shareholders is set for 36 months from the date of the initial public offering[32] - The company has implemented a strategy to maintain shareholder confidence through strict adherence to shareholding commitments[31] - The company has outlined clear guidelines for share transfers to prevent market disruption[32] - The commitment to not repurchase shares during the lock-up period reinforces the company's stability and investor trust[31] Investment and Projects - The company has completed the construction of a "consistency evaluation center for oral solid preparations," aiming for improved operational performance in 2016[22] - The clinical research service network expansion project has a total investment commitment of CNY 9,125.11 million, with a progress rate of 6.96% as of April 30, 2016[40] - The pharmaceutical research center expansion project has a total investment commitment of CNY 5,636.83 million, with a progress rate of 18.48% as of December 31, 2016[40] - The drug evaluation center construction project has a total investment commitment of CNY 4,077.63 million, with a progress rate of 8.76% as of April 30, 2016[40] - Total fundraising amount reached CNY 188.54 million, with CNY 7.86 million invested in the current quarter[39] Market and Competition - The company faces risks related to policy changes that could impact new drug development and approval processes[10] - Clinical trial project progress has slowed, affecting performance in Q1 2016, with no certainty on the impact for the full year[10] - The company anticipates significant market demand growth in the CRO industry due to new government policies encouraging innovation[20] - The company faces increased competition from multinational CROs establishing branches in China, which may lead to direct competition in international multi-center clinical research[26] - Domestic pharmaceutical companies are becoming more cautious in R&D investments due to high risks, price reductions, and limited overall revenue, potentially impacting the number and value of projects the company can undertake[26] Compliance and Governance - The company has committed to ensuring no false records or misleading statements in its prospectus, taking legal responsibility for accuracy and completeness[35] - The company and its major shareholders have pledged to avoid any actions that could infringe on the rights of other shareholders[36] - The company has maintained compliance with its commitments regarding related party transactions, ensuring fairness and normal commercial terms[36] - There are no reported instances of unfulfilled commitments or overdue obligations[37] - The company has confirmed that all commitments made to minority shareholders have been fulfilled on time[37]

Financial Performance - Net profit attributable to shareholders increased by 3.37% to CNY 4,933,828.31 for the current period[9] - Total operating revenue decreased by 11.63% to CNY 24,892,947.22 for the current period[9] - Basic earnings per share remained at CNY 0.04, unchanged from the previous period[9] - The weighted average return on net assets was 1.54%, a decrease of 0.83% compared to the previous period[9] - The net cash flow from operating activities was CNY -7,205,571.68, a decrease of 55.18% compared to the previous year[9] - The company achieved total operating revenue of 86.26 million yuan in the first nine months of 2015, representing a year-on-year growth of 7.18%[28] - Net profit attributable to shareholders for the same period was 17.31 million yuan, an increase of 6.11% compared to the previous year[28] - Clinical research service revenue reached 71.79 million yuan, growing by 7.27% year-on-year[28] - The total operating revenue for the third quarter was CNY 24,892,947.22, a decrease of 4.4% compared to CNY 28,168,140.27 in the same period last year[65] - The net profit for the third quarter was CNY 4,933,828.31, compared to CNY 4,772,750.72 in the same period last year, representing an increase of approximately 3.37%[67] Assets and Liabilities - Total assets increased by 64.67% to CNY 510,919,286.78 compared to the end of the previous year[9] - The total liabilities decreased to CNY 86,587,861.46 from CNY 91,779,339.10, indicating a reduction in financial obligations[59] - The equity attributable to shareholders increased to CNY 424,331,425.32 from CNY 218,483,709.07, reflecting strong retained earnings growth[60] - The company's cash and cash equivalents increased by 111.61% to ¥248,865,441.68 due to funds raised from a public stock offering[25] - The total current assets increased to ¥418,311,302.87 from ¥218,806,674.97, indicating a growth of about 91%[57] Shareholder Information - The total number of shareholders at the end of the reporting period is 9,025[20] - Wang Tingchun holds 38.78% of the shares, amounting to 25,855,000 shares[20] - The company has committed to not transferring or entrusting the management of its shares for 36 months following its initial public offering[38] - The controlling shareholder has pledged that any share reduction after the lock-up period will not exceed 5%-15% of the total share capital post-IPO[38] - The company has established a mechanism for shareholder announcements regarding share reductions[39] Investment and Fundraising - Total fundraising amount reached CNY 188.54 million, with CNY 6.38 million invested in the current quarter[47] - Cumulative investment from fundraising amounts to CNY 6.38 million, representing 2.25% of the clinical research service network expansion project[47] - The pharmaceutical research center expansion project received CNY 377.19 million, accounting for 6.69% of its total commitment[47] - The company allocated ¥47 million from the fundraising for the expansion of the pharmaceutical research center to its wholly-owned subsidiary, Technology Park Company[51] - The company approved an investment of ¥30 million to establish a wholly-owned subsidiary, Tibet Boji Investment Management Co., Ltd., which was registered on July 8, 2015[49] Operational Challenges and Strategies - The company faces risks related to long-cycle contracts in new drug development, which may impact future revenue and profitability[13] - Changes in national drug approval policies may affect the company's new drug research and registration progress, impacting business operations[17] - The company plans to enhance internal management and improve research service levels to strengthen its competitive advantage and risk resilience[17] - The company faces intensified competition from both domestic and international CROs, necessitating improvements in marketing and service levels[18] - The company is actively expanding its clinical research services and has established a nationwide monitoring service network to enhance market share[32] Compliance and Governance - The company has committed to ensuring the accuracy and completeness of its prospectus, taking legal responsibility for any misleading statements or omissions[43] - The company has established a framework to manage related party transactions fairly and reasonably, ensuring compliance with normal commercial practices[43] - The company has emphasized the importance of maintaining transparency and accountability in its financial disclosures to protect investor interests[43] - The company has reiterated its dedication to ethical governance and compliance with regulatory standards in all its operations[43] Cash Flow and Financial Management - The cash flow from operating activities showed a net outflow of CNY -7,205,571.68, an improvement from CNY -16,075,884.74 in the previous year[81] - The company reported a net increase in cash and cash equivalents of 111,799,904.16 CNY, compared to a decrease of -63,464,444.85 CNY in the previous period[86] - Total cash inflow from financing activities amounted to 196,234,039.00 CNY, while cash outflow was 6,953,335.00 CNY, resulting in a net cash flow of 189,280,704.00 CNY[85] - The company incurred investment cash outflows of 89,564,645.42 CNY, up from 23,288,293.68 CNY in the previous period[85]

Financial Performance - Total revenue for the first half of 2015 was CNY 61,363,567.18, representing a 17.30% increase compared to CNY 52,311,532.08 in the same period last year[16]. - Net profit attributable to ordinary shareholders was CNY 12,377,741.74, up 7.24% from CNY 11,542,019.92 year-on-year[16]. - The operating profit for the same period was 14.12 million yuan, reflecting a growth of 6.22% year-on-year[30]. - Clinical research service revenue increased by 17.90% year-on-year, indicating a positive growth trend[31]. - The total comprehensive income for the period was CNY 13,620,810.61, compared to CNY 11,724,910.47 in the previous period, representing an increase of approximately 16.1%[124]. - The company reported a total comprehensive income of CNY 12,377,000 for the current period, which is a significant increase compared to the previous period[134]. Cash Flow and Liquidity - Net cash flow from operating activities improved significantly to CNY 746,011.06, a 106.78% increase from a negative CNY 11,011,139.57 in the previous year[16]. - Cash inflows from operating activities totaled CNY 66,871,341.22, up from CNY 45,686,649.42, indicating a growth of about 46.3%[127]. - The net cash flow from financing activities surged by 857.12% to ¥189,280,704.00, primarily due to funds raised from the company's IPO[34]. - The cash outflow for investing activities was CNY 2,178,599.02, down from CNY 7,154,739.02, indicating a reduction of approximately 69.5%[128]. - Cash and cash equivalents at the end of the period reached CNY 304,249,711.46, compared to CNY 94,944,285.58 at the end of the previous period, marking an increase of approximately 220.5%[128]. Assets and Liabilities - Total assets increased by 64.81% to CNY 511,356,335.03 from CNY 310,263,048.17 at the end of the previous year[16]. - Total liabilities slightly increased from CNY 91,779,339.10 to CNY 91,958,738.02, a change of about 0.2%[114]. - The company's equity surged from CNY 218,483,709.07 to CNY 419,397,597.01, indicating a growth of approximately 92%[114]. - Accounts receivable increased from CNY 57,084,103.96 to CNY 63,261,298.90, reflecting a growth of approximately 10.3%[111]. - Inventory grew from CNY 36,047,593.47 to CNY 41,945,354.16, marking an increase of about 16.5%[112]. Share Capital and Equity Structure - The company plans to increase its total share capital from 66.67 million shares to 133.34 million shares through a capital reserve transfer, with no cash dividends or bonus shares distributed[5]. - The profit distribution plan for the reporting period includes a capital reserve transfer of 10 shares for every 10 shares held, resulting in a total share capital increase to 133,340,000 shares[60]. - The total number of shares increased from 50,000,000 to 66,670,000 shares following the public offering of 16,670,000 shares on April 24, 2015[95]. - Major shareholder Wang Tingchun holds 38.78% of the shares, totaling 25,855,000 shares[99]. - The total number of shareholders at the end of the reporting period was 9,363[99]. Governance and Compliance - The company is focused on enhancing its governance structure and compliance with legal regulations to improve operational efficiency[32]. - The company has committed to maintaining stable stock prices for three years post-IPO, with specific measures in place to prevent share transfers that could affect control[85]. - The company has established a framework for managing shareholding structures to ensure long-term stability and growth[84]. - The company has committed to not engaging in any competitive activities with its subsidiaries during the tenure of its shareholders[88]. - The company confirmed that there are no false records or misleading statements in its prospectus, taking legal responsibility for the accuracy of the information[86]. Risks and Challenges - The company faces risks related to long-cycle contracts in new drug research, which may impact future revenue and profitability[21]. - The company is facing increased competition from both domestic and international CROs, necessitating improvements in marketing and service levels[26]. Research and Development - Research and development investment rose by 3.47% to ¥3,853,500.66, indicating a continued focus on innovation[34]. - The company received a patent for a traditional Chinese medicine composition for treating depression, enhancing its innovation capabilities[31]. - The company is actively expanding its clinical research services into post-marketing evaluation and international multi-center studies[31]. Audit and Financial Reporting - The semi-annual financial report has been audited and is consistent with the previous annual report[89]. - The audit report issued on August 19, 2015, confirmed a standard unqualified opinion, indicating the financial statements are free from material misstatement[110]. - The financial statements were approved by the board of directors on August 19, 2015[146]. Future Outlook - The company is focused on expanding its market presence and enhancing its research and development capabilities in the biotechnology sector[144]. - The company has plans for future product launches and technological advancements to strengthen its competitive position in the market[144]. - The company aims to improve its operational efficiency and explore potential mergers and acquisitions to drive growth[144].